AU2006225515B2 - Method and composition for treating mucosal disorders - Google Patents

Method and composition for treating mucosal disorders Download PDF

Info

Publication number
AU2006225515B2
AU2006225515B2 AU2006225515A AU2006225515A AU2006225515B2 AU 2006225515 B2 AU2006225515 B2 AU 2006225515B2 AU 2006225515 A AU2006225515 A AU 2006225515A AU 2006225515 A AU2006225515 A AU 2006225515A AU 2006225515 B2 AU2006225515 B2 AU 2006225515B2
Authority
AU
Australia
Prior art keywords
prostaglandin
compound
prostaglandin compound
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006225515A
Other languages
English (en)
Other versions
AU2006225515A1 (en
AU2006225515A8 (en
Inventor
Anthony T. Blikslager
Sachiko Kuno
Adam J. Moeser
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
North Carolina State University
Original Assignee
Sucampo GmbH
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH, North Carolina State University filed Critical Sucampo GmbH
Publication of AU2006225515A1 publication Critical patent/AU2006225515A1/en
Publication of AU2006225515A8 publication Critical patent/AU2006225515A8/en
Application granted granted Critical
Publication of AU2006225515B2 publication Critical patent/AU2006225515B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2006225515A 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders Ceased AU2006225515B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US66320005P 2005-03-21 2005-03-21
US60/663,200 2005-03-21
US67992005P 2005-05-11 2005-05-11
US60/679,920 2005-05-11
US72197605P 2005-09-30 2005-09-30
US60/721,976 2005-09-30
PCT/JP2006/306380 WO2006101244A2 (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders

Publications (3)

Publication Number Publication Date
AU2006225515A1 AU2006225515A1 (en) 2006-09-28
AU2006225515A8 AU2006225515A8 (en) 2006-09-28
AU2006225515B2 true AU2006225515B2 (en) 2012-02-02

Family

ID=36754577

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006225515A Ceased AU2006225515B2 (en) 2005-03-21 2006-03-22 Method and composition for treating mucosal disorders

Country Status (14)

Country Link
US (1) US20060281818A1 (enExample)
EP (3) EP2384790A3 (enExample)
JP (2) JP5219797B2 (enExample)
KR (2) KR101456298B1 (enExample)
CN (1) CN103948603A (enExample)
AU (1) AU2006225515B2 (enExample)
BR (1) BRPI0609672A2 (enExample)
CA (2) CA2601158C (enExample)
ES (1) ES2592283T3 (enExample)
IL (1) IL185861A (enExample)
MX (1) MX2007011645A (enExample)
NO (1) NO20075361L (enExample)
NZ (3) NZ597857A (enExample)
WO (1) WO2006101244A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7868045B2 (en) 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
CN101918017B (zh) * 2007-10-25 2013-07-31 植物药学公司 Phy906用于治疗炎性肠病和/或肠易激综合征的用途
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US20100305203A1 (en) * 2009-05-27 2010-12-02 Sucampo Ag Method for modulating claudin mediated functions
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
JP2014515004A (ja) * 2011-04-27 2014-06-26 スキャンポ・アーゲー イオン輸送体の調節方法
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease
EP3292135B1 (en) * 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2024217532A1 (zh) * 2023-04-20 2024-10-24 中南大学湘雅二医院 Carboprost在制备抗肿瘤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
GB1581886A (en) * 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPS58216155A (ja) * 1982-06-10 1983-12-15 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
JPS591463A (ja) * 1982-06-28 1984-01-06 Ono Pharmaceut Co Ltd 新規なプロスタグランジンｄ類似化合物
FR2608924B1 (fr) * 1986-12-29 1990-07-20 Pasteur Institut Compositions therapeutiques contenant des derives soufres de prostaglandines, nouveaux derives soufres et leur procede de preparation
CA1323364C (en) * 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) * 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
US5234858A (en) 1990-11-16 1993-08-10 Micron Technology, Inc. Stacked surrounding wall capacitor
KR940007277B1 (ko) 1992-02-14 1994-08-12 한국과학기술원 2차 전지 전극용 수소 저장 합금
US5376034A (en) 1992-05-27 1994-12-27 Brunswick Corporation Marine drive exhaust system
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
US5876034A (en) 1997-12-17 1999-03-02 Stafford; James R. Sporting fishing board game
US6492417B1 (en) * 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
GB2375349A (en) * 2001-02-13 2002-11-13 Glaxo Group Ltd Chloride intracellular channel-related proteins
US6919082B2 (en) * 2001-02-13 2005-07-19 Kirin Beer Kabushiki Kaisha Pharmacological composition containing yeast cell wall fraction
GB0111497D0 (en) * 2001-05-11 2001-07-04 Medical Res Council Therapeutic methods
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
JP4889219B2 (ja) * 2002-12-27 2012-03-07 スキャンポ・アーゲー 腹部不快感の処置のためのプロスタグランジン誘導体
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US7169807B2 (en) * 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATO T. et al: Cancer Research, vol. 46, no. 7,1986, pages 3538-3542. *

Also Published As

Publication number Publication date
KR20140072102A (ko) 2014-06-12
CA2601158A1 (en) 2006-09-28
EP2384790A2 (en) 2011-11-09
BRPI0609672A2 (pt) 2010-04-20
IL185861A (en) 2015-06-30
EP1861169A2 (en) 2007-12-05
AU2006225515A1 (en) 2006-09-28
NZ597857A (en) 2013-08-30
AU2006225515A8 (en) 2006-09-28
EP2384791A3 (en) 2011-12-28
KR20080012266A (ko) 2008-02-11
US20060281818A1 (en) 2006-12-14
WO2006101244A2 (en) 2006-09-28
CA2831416C (en) 2016-12-13
EP2384791A2 (en) 2011-11-09
KR101456298B1 (ko) 2014-11-03
CN103948603A (zh) 2014-07-30
NZ562351A (en) 2010-12-24
CA2601158C (en) 2015-10-13
IL185861A0 (en) 2008-01-06
JP2012180380A (ja) 2012-09-20
ES2592283T3 (es) 2016-11-29
EP1861169B1 (en) 2016-05-11
JP5219797B2 (ja) 2013-06-26
JP5777574B2 (ja) 2015-09-09
JP2008533195A (ja) 2008-08-21
NO20075361L (no) 2007-12-20
NZ588878A (en) 2012-05-25
CA2831416A1 (en) 2006-09-28
WO2006101244A3 (en) 2007-02-08
EP2384791B1 (en) 2016-06-15
EP2384790A3 (en) 2011-12-28
MX2007011645A (es) 2007-11-16

Similar Documents

Publication Publication Date Title
JP5777574B2 (ja) 粘膜障害の処置のための方法および組成物
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
EP1871380B1 (en) Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
RU2440338C2 (ru) Способ и композиция для лечения заболеваний центральной нервной системы
AU2003274735A1 (en) Prostaglandin compounds for the treatment of obesity
CN101180096B (zh) 用于治疗粘膜疾病的方法和组合物
RU2445961C2 (ru) Способ и композиция для лечения повреждений слизистых оболочек
AU2010253720A1 (en) Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 21, NO 43, PAGE(S) 4969 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SUCAMPO AG, APPLICATION NO. 2006225515, UNDER INID (71) ADD THE AP- PLICANT NORTH CAROLINA STATE UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired